BANK VONTOBEL/CALL/BIOGEN IDEC/280/0.1/20.12.24 | Delayed Deutsche Boerse AG 10:52:38 2024-05-20 EDT | ||
| 0.9 EUR | +3.45% |
|
| Current month | +47.46% | ||
| 1 month | +135.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 0.9 | +3.45% |
| 24-05-17 | 0.87 | -4.40% |
| 24-05-16 | 0.91 | -18.02% |
| 24-05-15 | 1.11 | +40.51% |
| 24-05-14 | 0.79 | -3.66% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 10:52 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM7SCT |
| ISIN | DE000VM7SCT1 |
| Date issued | 2024-01-02 |
| Strike | 280 $ |
| Maturity | 2024-12-20 (214 Days) |
| Parity | 10 : 1 |
| Emission price | 2.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.61 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.03 € |
| Spread % | 3.19% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
285.9
USD
Spread / Average Target
+24.01%
- Stock Market
- Warrants
- Warrant
